Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2025
Advanced gallbladder cancer (T3 and T4): insights from an international multicenter study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chirban Ariana M, Rivera Belen, Kawahara William, Mellado Sebastian, Niakosari Melika, Okuno Masayuki, Panettieri Elena, De Bellis Mario, Kristjanpoller Werner, Merlo Ignacio, Serenari Matteo, Donadon Matteo, Newhook Timothy E, de Aretxabala Xabier, Vivanco Marcelo, Brudvik Kristoffer W, Seo Satoru, Pekolj Juan, Poultsides George A, De Rose Agostino Maria, Torzilli Guido, Giuliante Felice, Denbo Jason, Anaya Daniel A, Vinuela Eduardo, Tzeng Ching-Wei D, Vauthey Jean-Nicolas, Ruzzenente Andrea, Vega Eduardo A
Аннотация
BACKGROUND: Surgical resection is the only curative treatment of gallbladder cancer (GBC). However, the role of oncologic extended resection (OER) in advanced GBC (T3/T4) remains unclear. This study aimed to evaluate the effect of OER in patients with advanced GBC.
METHODS: This retrospective, multicenter study analyzed 419 patients diagnosed with GBC at 17 institutions across 7 countries between 1997 and 2022. Adjusted logistic regression was used to examine factors affecting R1 resection and lymph node positivity. Survival was assessed using Kaplan-Meier curves and multivariate Cox proportional hazards.
RESULTS: Of the cohort, 369 patients with T3 GBC and 50 patients with T4 GBC were identified. Predictors of R1 status for patients with T3/T4 GBC included jaundice before surgery (odds ratio [OR], 3.03 [95% CI, 1.68-5.45]), perineural and/or lymphovascular invasion (OR, 2.43 [95% CI, 1.35-4.39]), adjacent organ resection (OR, 2.05 [95% CI, 1.09-3.85]), overall morbidity (OR, 1.64 [95% CI, 1.01-2.66]), and lymph node metastasis (OR, 2.69 [95% CI, 1.55-4.66]). Morbidity was higher in patients (64.8%) with T4 GBC than in patients (38.2%) with T3 GBC, with severe morbidity at 46.3% and 17.1%, respectively. Of note, 90-day mortality was 4.1% for patients with T3 GBC and 12% for patients with T4 GBC. The 3-year overall survival rate was 33% for patients with T3 GBC and 4% for patients with T4 GBC (log-rank P <.001).
CONCLUSION: Advanced-stage GBC outcomes vary with resection status. OER is associated with increased morbidity, particularly in patients with T4 GBC, for whom survival benefits are limited. Careful patient selection for aggressive surgical treatment is crucial to avoid unnecessary morbidity while carefully weighing the potential survival benefits.
METHODS: This retrospective, multicenter study analyzed 419 patients diagnosed with GBC at 17 institutions across 7 countries between 1997 and 2022. Adjusted logistic regression was used to examine factors affecting R1 resection and lymph node positivity. Survival was assessed using Kaplan-Meier curves and multivariate Cox proportional hazards.
RESULTS: Of the cohort, 369 patients with T3 GBC and 50 patients with T4 GBC were identified. Predictors of R1 status for patients with T3/T4 GBC included jaundice before surgery (odds ratio [OR], 3.03 [95% CI, 1.68-5.45]), perineural and/or lymphovascular invasion (OR, 2.43 [95% CI, 1.35-4.39]), adjacent organ resection (OR, 2.05 [95% CI, 1.09-3.85]), overall morbidity (OR, 1.64 [95% CI, 1.01-2.66]), and lymph node metastasis (OR, 2.69 [95% CI, 1.55-4.66]). Morbidity was higher in patients (64.8%) with T4 GBC than in patients (38.2%) with T3 GBC, with severe morbidity at 46.3% and 17.1%, respectively. Of note, 90-day mortality was 4.1% for patients with T3 GBC and 12% for patients with T4 GBC. The 3-year overall survival rate was 33% for patients with T3 GBC and 4% for patients with T4 GBC (log-rank P <.001).
CONCLUSION: Advanced-stage GBC outcomes vary with resection status. OER is associated with increased morbidity, particularly in patients with T4 GBC, for whom survival benefits are limited. Careful patient selection for aggressive surgical treatment is crucial to avoid unnecessary morbidity while carefully weighing the potential survival benefits.